ALKS Add to watchlist $33.22 0.65 (-1.92%) Last updated: Apr 16, 2026 02:30
52-Week Range
$33.22
$25.17 $33.22 $36.48

Fundamentals Overview

Alkermes plc is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 23.2 P/B 3.01 P/S 3.75

Intrinsic value (DCF)

+19.3% upside vs price

Profitability

Net margin 16.4%

Risk (Beta)

0.39 — lower vol

Earnings & growth

EPS $1.43 Rev -2.4% Profit -40.4% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 80% confidence Risk: Lower Volatility — Beta 0.39. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +19.3% upside vs price · Analyst grade: A- · Sentiment improving (3 upgrades) · 3M vs S&P 500: +11.5% · 3M vs Healthcare sector: +18.3%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$5.54B
P/E (TTM)
23.2
EPS (TTM)
$1.43
Dividend Yield
N/A
52-Week Range
$25.17 - $36.48
Volume vs Avg
N/A
Beta
0.39

About

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; IN...
Sector: Healthcare
Headquarters: IE
Employees: 1,800
IPO Date: Jul 1991
Beta: 0.39 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A-. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 9, Neutral: 8, Outperform: 6, Overweight: 5, Sector Perform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $39.63; current price is $33.22. That’s a +19.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 23.2
DCF value (model) $39.63 (19.3% upside)
PEG (TTM) N/A
P/B (TTM) 3.01
P/S (TTM) 3.75
P/FCF (TTM) 11.53
Liquidity & enterprise
Current Ratio (TTM) 3.55
Quick Ratio (TTM) 3.19
Cash Ratio (TTM) 2.06
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 16.37%
Gross margin (TTM) 86.31%
Operating margin (TTM) 17.21%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ALKS.

Analyst Sentiment at a Glance

A- Sentiment Improving
Buy 9Neutral 8Outperform 6Overweight 5Sector Perform 2
3 upgrades, 0 downgrades
Price Target Consensus
Current $33.22
Median $45.00
Consensus $46.83
Low consensus $43.00
High consensus $56.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
B of A Securities maintain Neutral Neutral 2026-04-09
Piper Sandler maintain Overweight Overweight 2026-03-24
Wells Fargo maintain Overweight Overweight 2026-02-26
RBC Capital maintain Outperform Outperform 2026-02-26
B of A Securities maintain Neutral Neutral 2026-02-20
Truist Securities maintain Buy Buy 2025-11-17
Wells Fargo maintain Overweight Overweight 2025-11-13
Deutsche Bank maintain Buy Buy 2025-11-13
Truist Securities maintain Buy Buy 2025-11-12
Wells Fargo maintain Overweight Overweight 2025-10-29
Needham maintain Buy Buy 2025-10-29
Mizuho maintain Outperform Outperform 2025-10-27
RBC Capital maintain Outperform Outperform 2025-10-23
Piper Sandler maintain Overweight Overweight 2025-10-23
RBC Capital upgrade Sector Perform Outperform 2025-09-26
HC Wainwright & Co. maintain Neutral Neutral 2025-09-09
JP Morgan maintain Neutral Neutral 2025-09-09
RBC Capital maintain Sector Perform Sector Perform 2025-07-30
Needham maintain Buy Buy 2025-07-29
HC Wainwright & Co. maintain Neutral Neutral 2025-07-21
Needham maintain Buy Buy 2025-07-21
UBS upgrade Neutral Buy 2025-06-17
RBC Capital maintain Sector Perform Sector Perform 2025-05-02
Baird maintain Outperform Outperform 2025-05-02
UBS maintain Neutral Neutral 2025-04-28
Deutsche Bank maintain Buy Buy 2025-03-27
UBS upgrade Sell Neutral 2025-03-04
Goldman Sachs maintain Buy Buy 2025-02-14
HC Wainwright & Co. maintain Neutral Neutral 2025-02-13
Mizuho maintain Outperform Outperform 2024-11-13